Boston, MA 02/19/2014 (wallstreetpr) – American Realty Capital Properties Inc (NASDAQ:ARCP) has reported that the company has now grown to be one of the most attractive services in the real estate investment sector. Of the several reasons for the company’s upside, one of the major include the Cole acquisition. This has proved to be worthy well and above the recent expectations and has generated quality cash flow for growth. Additionally, American Realty Capital Properties Inc (NASDAQ:ARCP) has also proved to be suitable for investors who need reliable retirement investments.
Johnson & Johnson (NYSE:JNJ) the leading stock last year for this segment, has seen a downward trend this year. Overcoming J&J on the stock market header-board is Merck, with its posse of drugs, products and more. There has been Merck’s bucket of woes overflowing last year, thanks to higher generic competitors and an increased phase of expiry of patents. The loss in both these sectors saw the profit margins drop for Merck. This time around Johnson and Johnson too has the same range of issues. However J&J is better placed as much of the revenue from generic competitors is low due to the low exposure to the same. The Medical Diagnostic as well as Consumer Goods has helped Johnson & Johnson (NYSE:JNJ) to post better results.
Eli Lilly & Co. (NYSE:LLY) now in the post-patent era of most of its exclusive products, is now on the hunt for new, promising drugs. The company with some long-term R& D as well as regulatory review time has reported that it is in a phase of searching for small acquisitions in the meanwhile. The President and CEO of Eli Lilly & Co. (NYSE:LLY), John Lechleiter did indicate that the company may not have an appetite for such investments which would require merger and acquisition processes. One of the latest drugs to expire in March is $1.05 billion, which is a bone-building drug called Evista.
For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com